Drug intelligence / Profile preview

TF06 + SE90

Development stage: Unknown
Lead developer: 深圳扬厉医药
Modality: Small Molecules
Administration: Oral

Overview

TF06 + SE90 is an investigational therapeutic combination or dual-targeting agent developed by Zhejiang Yangli Pharmaceutical Technology (also known as VyBio) for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The drug is designed to simultaneously target the estrogen receptor (ER) and the HER2 pathways, addressing potential resistance mechanisms in hormone receptor-positive breast cancer. It is currently in Phase 2/3 clinical development, being evaluated both as a monotherapy and in combination with CDK4/6 inhibitors for patients who have progressed on prior endocrine therapies.

Targets

ER (Estrogen receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on TF06 + SE90.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TF06 + SE90.

Explore the full profile